[{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Khon Kaen University","sponsor":"National Research Council of Thailand | Srinagarind Hospital, Khon Kaen University | Maharat Hospital, Nakhon Ratchasima | General Drugs House Co.,LTD.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"THAILAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Khon Kaen University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Khon Kaen University \/ National Research Council of Thailand | Srinagarind Hospital, Khon Kaen University | Maharat Hospital, Nakhon Ratchasima | General Drugs House Co.,LTD.","highestDevelopmentStatusID":"9","companyTruncated":"Khon Kaen University \/ National Research Council of Thailand | Srinagarind Hospital, Khon Kaen University | Maharat Hospital, Nakhon Ratchasima | General Drugs House Co.,LTD."},{"orgOrder":0,"company":"Khon Kaen University","sponsor":"Ubon Ratchathani Cancer Hospital, Ubon Ratchathani | General Drugs House Co.,LTD.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"THAILAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Khon Kaen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Khon Kaen University \/ Ubon Ratchathani Cancer Hospital, Ubon Ratchathani | General Drugs House Co.,LTD.","highestDevelopmentStatusID":"8","companyTruncated":"Khon Kaen University \/ Ubon Ratchathani Cancer Hospital, Ubon Ratchathani | General Drugs House Co.,LTD."},{"orgOrder":0,"company":"Khon Kaen University","sponsor":"Khon Kaen Hospital, Khon Kaen | General Drugs House Co.,LTD. | Thailand Research Fund | Srinagarind Hospital, Khon Kaen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"THAILAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Khon Kaen University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khon Kaen University \/ Khon Kaen Hospital, Khon Kaen | General Drugs House Co.,LTD. | Thailand Research Fund | Srinagarind Hospital, Khon Kaen University","highestDevelopmentStatusID":"9","companyTruncated":"Khon Kaen University \/ Khon Kaen Hospital, Khon Kaen | General Drugs House Co.,LTD. | Thailand Research Fund | Srinagarind Hospital, Khon Kaen University"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kuhnil Pharmaceutical, Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kuhnil Pharmaceutical, Co. Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Kuhnil Pharmaceutical, Co. Ltd"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Odense University Hospital \/ University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","highestDevelopmentStatusID":"10","companyTruncated":"Odense University Hospital \/ University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation"},{"orgOrder":0,"company":"Zealand University Hospital","sponsor":"Psychiatric Research Unit, Region Zealand, Denmark | University of Copenhagen | Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Zealand University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand University Hospital \/ Psychiatric Research Unit, Region Zealand, Denmark | University of Copenhagen | Pharma Nord","highestDevelopmentStatusID":"9","companyTruncated":"Zealand University Hospital \/ Psychiatric Research Unit, Region Zealand, Denmark | University of Copenhagen | Pharma Nord"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PiLeJe \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Undisclosed"},{"orgOrder":0,"company":"Concordia Dent Srl","sponsor":"Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Concordia Dent Srl","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Concordia Dent Srl \/ Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Concordia Dent Srl \/ Carol Davila University of Medicine and Pharmacy | Romanian National Authority for Scientific Research and Innovation | University Politechnica of Bucharest | TURKEY MEDISEN Ltd"},{"orgOrder":0,"company":"Fundacion Rioja Salud","sponsor":"Pharmamel | Universidad de Granada | Instituto de Salud Carlos III","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Fundacion Rioja Salud","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fundacion Rioja Salud \/ Pharmamel | Universidad de Granada | Instituto de Salud Carlos III","highestDevelopmentStatusID":"1","companyTruncated":"Fundacion Rioja Salud \/ Pharmamel | Universidad de Granada | Instituto de Salud Carlos III"},{"orgOrder":0,"company":"Technological Centre of Nutrition and Health, Spain","sponsor":"Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | Plantas Medicinales y Complementos Alimenticios, S.A. | University Rovira i Virgili","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Technological Centre of Nutrition and Health, Spain","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technological Centre of Nutrition and Health, Spain \/ Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | Plantas Medicinales y Complementos Alimenticios, S.A. | University Rovira i Virgili","highestDevelopmentStatusID":"8","companyTruncated":"Technological Centre of Nutrition and Health, Spain \/ Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | Plantas Medicinales y Complementos Alimenticios, S.A. | University Rovira i Virgili"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Hospital Vall d'Hebron | Laboratorio Echevarne","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Hospital Vall d'Hebron | Laboratorio Echevarne","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Hospital Vall d'Hebron | Laboratorio Echevarne"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Laboratorio Echevarne | Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron"},{"orgOrder":0,"company":"Spherium Biomed","sponsor":"Institut Catal\u00e0 d'Oncologia L'Hospitalet | Hospital Universitari de la Vall de Hebron | Hospital de la Santa Creu i Sant Pau | Institut Catal\u00e0 d'Oncologia ICO Girona | Institut Catal\u00e0 d'Oncologia ICO Badalona | Hospital Miguel Servet | Hospital Universita","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Spherium Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spherium Biomed \/ Institut Catal\u00e0 d'Oncologia L'Hospitalet | Hospital Universitari de la Vall de Hebron | Hospital de la Santa Creu i Sant Pau | Institut Catal\u00e0 d'Oncologia ICO Girona | Institut Catal\u00e0 d'Oncologia ICO Badalona | Hospital Miguel Servet | Hospital Universita","highestDevelopmentStatusID":"7","companyTruncated":"Spherium Biomed \/ Institut Catal\u00e0 d'Oncologia L'Hospitalet | Hospital Universitari de la Vall de Hebron | Hospital de la Santa Creu i Sant Pau | Institut Catal\u00e0 d'Oncologia ICO Girona | Institut Catal\u00e0 d'Oncologia ICO Badalona | Hospital Miguel Servet | Hospital Universita"},{"orgOrder":0,"company":"MICE Trial Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"MICE Trial Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MICE Trial Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MICE Trial Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Ritual Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Ritual Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Ritual Inc."},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Neurim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Scripps Health \/ Undisclosed"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Scripps Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ Scripps Health","highestDevelopmentStatusID":"7","companyTruncated":"Scripps Health \/ Scripps Health"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Vedistry Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Vedistry Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Vedistry Private Limited"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Sunnybrook Health Sciences Centre | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mount Sinai Hospital, Canada \/ Sunnybrook Health Sciences Centre | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al","highestDevelopmentStatusID":"8","companyTruncated":"Mount Sinai Hospital, Canada \/ Sunnybrook Health Sciences Centre | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al"},{"orgOrder":0,"company":"Fraser Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Fraser Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraser Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fraser Health \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"National Library of Medicine | Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ National Library of Medicine | Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ National Library of Medicine | Columbia University"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Providence Health & Services \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Pharmavite","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ KGK Science","highestDevelopmentStatusID":"6","companyTruncated":"Pharmavite \/ KGK Science"},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Kinderfarms","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinderfarms \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kinderfarms \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Larena SAS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"COLOMBIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Larena SAS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larena SAS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Larena SAS \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Gustav Stalhammar","sponsor":"Karolinska Trial Alliance | Swedish Eye Foundation (\u00d6gonfonden) | Swedish Society of Medicine | Swedish Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Gustav Stalhammar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gustav Stalhammar \/ Karolinska Trial Alliance | Swedish Eye Foundation (\u00d6gonfonden) | Swedish Society of Medicine | Swedish Cancer Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Gustav Stalhammar \/ Karolinska Trial Alliance | Swedish Eye Foundation (\u00d6gonfonden) | Swedish Society of Medicine | Swedish Cancer Foundation"},{"orgOrder":0,"company":"Pharmamel","sponsor":"Hospital Universitario La Paz | Instituto de Investigaci\u00f3n Hospital Universitario La Paz","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharmamel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmamel \/ Hospital Universitario La Paz | Instituto de Investigaci\u00f3n Hospital Universitario La Paz","highestDevelopmentStatusID":"8","companyTruncated":"Pharmamel \/ Hospital Universitario La Paz | Instituto de Investigaci\u00f3n Hospital Universitario La Paz"},{"orgOrder":0,"company":"Melissa Voigt Hansen","sponsor":"University of Copenhagen | Rigshospitalet | Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Melissa Voigt Hansen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melissa Voigt Hansen \/ University of Copenhagen | Rigshospitalet | Pharma Nord","highestDevelopmentStatusID":"9","companyTruncated":"Melissa Voigt Hansen \/ University of Copenhagen | Rigshospitalet | Pharma Nord"},{"orgOrder":0,"company":"Lone Baandrup","sponsor":"Danish Center for Sleep Medicine | Region Capital Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research | Mental Health Services in the Capital Region, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Lone Baandrup","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lone Baandrup \/ Danish Center for Sleep Medicine | Region Capital Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research | Mental Health Services in the Capital Region, Denmark","highestDevelopmentStatusID":"9","companyTruncated":"Lone Baandrup \/ Danish Center for Sleep Medicine | Region Capital Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research | Mental Health Services in the Capital Region, Denmark"},{"orgOrder":0,"company":"Dennis Bregner Zetner","sponsor":"Copenhagen University Hospital, Denmark | RepoCeuticals | Herlev Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dennis Bregner Zetner","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dennis Bregner Zetner \/ Copenhagen University Hospital, Denmark | RepoCeuticals | Herlev Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Dennis Bregner Zetner \/ Copenhagen University Hospital, Denmark | RepoCeuticals | Herlev Hospital"},{"orgOrder":0,"company":"Institute of Nutrition, Slovenia (Nutris)","sponsor":"Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SLOVENIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"Institute of Nutrition, Slovenia (Nutris)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Institute of Nutrition, Slovenia (Nutris) \/ Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Nutrition, Slovenia (Nutris) \/ Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija"},{"orgOrder":0,"company":"Kuhnil Pharmaceutical, Co. Ltd","sponsor":"KIMJisun","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Kuhnil Pharmaceutical, Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuhnil Pharmaceutical, Co. Ltd \/ KIMJisun","highestDevelopmentStatusID":"11","companyTruncated":"Kuhnil Pharmaceutical, Co. Ltd \/ KIMJisun"}]
Find Clinical Drug Pipeline Developments & Deals for Melatonin
Details :
Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.
Sponsor :
Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija
Details :
Melatonin is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Sleep Latency.
Sponsor :
Faculty of Pharmacy, University of Ljubljana, Slovenia | Faculty of health sciences, Celje, Slovenia | CMS - Center za motnje spanja, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija
Details :
Slenyto is a child appropriate Extended-release oral minitablet (only 3mm diameter), containing melatonin, a naturally occurring hormone that regulates the sleep-wake cycle.
Details :
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.
Details :
IGC-AD1 is a cannabinoid-based partial CB1 receptor agonist with anti-neuroinflammatory and neuroprotective properties. It is being evaluated for the treatment of dementia due to Alzheimer's disease.
Details :
Slenyto is a prolonged-release formulation of melatonin, which is indicated for the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD).
Details :
Slenyto (melatonin) is an approved melatonin receptor agonist, which is currently being evaluated for the treatment of insomnia in children with neurogenetic disorders.
Sponsor :
University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Details :
Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Low Back Pain.
Sponsor :
University of Southern Denmark | T&W Engineering | University of Aarhus | Open Patient data Explorative Network | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
